By Denny Jacob
Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.
The companies said they expect to file an investigational new drug application for their dual agonist GLP-1/glucagon peptide as a once-daily tablet with the Food and Drug Administration later this year.
Under the terms, Opko and Entera will hold 60% and 40% pro-rata ownership interests, respectively, in the program and be responsible for 60% and 40% of the program's development costs.
Opko purchased around 3.7 million ordinary shares of Entera for a purchase price equal to $2.17 a share in connection with the agreement. Entera agreed to utilize the proceeds from the sale of the shares to fund its 40% share of costs through Phase 1 of the development program.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 17, 2025 08:57 ET (12:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.